Autoimmunity risk alleles in costimulation pathways

Immunological Reviews

Volumn 229, Issue 1, 2009, Pages 322-336

  Maier, Lisa M ^a,b   Hafler, David A ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

Autoimmunity; Costimulation; Risk alleles

Indexed keywords

CD40 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; OX40 LIGAND; VASCULAR ENDOTHELIAL GROWTH INHIBITOR;

ALLELE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; GENETIC ASSOCIATION; HAPLOTYPE; HUMAN; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

ALLELES; AUTOIMMUNE DISEASES; AUTOIMMUNITY; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES;

EID: 65349131842     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/j.1600-065X.2009.00777.x     Document Type: Review

References (130)

1. Fernando MM, et al. Defining the role of the MHC in autoimmunity: a review and pooled analysis. PLoS Genet 2008 4 : e1000024.
2. Lohmueller KE, Pearce CL, Pike M, Lander ES, Hirschhorn JN. Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat Genet 2003 33 : 177 182.
3. Colhoun HM, McKeigue PM, Davey Smith G. Problems of reporting genetic associations with complex outcomes. Lancet 2003 361 : 865 872.
4. Ioannidis JP, Trikalinos TA, Ntzani EE, Contopoulos-Ioannidis DG. Genetic associations in large versus small studies: an empirical assessment. Lancet 2003 361 : 567 571.
5. Wang WY, Barratt BJ, Clayton DG, Todd JA. Genome-wide association studies: theoretical and practical concerns. Nat Rev Genet 2005 6 : 109 118.
6. Barreto M, et al. Evidence for CTLA4 as a susceptibility gene for systemic lupus erythematosus. Eur J Hum Genet 2004 12 : 620 626.
7. Cunninghame Graham DS, Wong AK, McHugh NJ, Whittaker JC, Vyse TJ. Evidence for unique association signals in SLE at the CD28-CTLA4-ICOS locus in a family-based study. Hum Mol Genet 2006 15 : 3195 3205.
8. Plenge RM, et al. Replication of putative candidate-gene associations with rheumatoid arthritis in >4,000 samples from North America and Sweden: association of susceptibility with PTPN22, CTLA4, and PADI4. Am J Hum Genet 2005 77 : 1044 1060.
9. Raychaudhuri S, et al. Common variants at CD40 and other loci confer risk of rheumatoid arthritis. Nat Genet 2008 40 : 1216 1223.
10. Smyth DJ, et al. Shared and distinct genetic variants in type 1 diabetes and celiac disease. N Engl J Med 2008 359 : 2767 2777.
11. Ueda H, et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003 423 : 506 511.
12. Howson JM, Dunger DB, Nutland S, Stevens H, Wicker LS, Todd JA. A type 1 diabetes subgroup with a female bias is characterised by failure in tolerance to thyroid peroxidase at an early age and a strong association with the cytotoxic T-lymphocyte-associated antigen-4 gene. Diabetologia 2007 50 : 741 746.
13. Todd JA, et al. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat Genet 2007 39 : 857 864.
14. Rioux JD, et al. Genomewide search and association studies in a Finnish celiac disease population: Identification of a novel locus and replication of the HLA and CTLA4 loci. Am J Med Genet A 2004 130A : 345 350.
15. van Heel DA, et al. A genome-wide association study for celiac disease identifies risk variants in the region harboring IL2 and IL21. Nat Genet 2007 39 : 827 829.
16. Scalapino KJ, Daikh DI. CTLA-4: a key regulatory point in the control of autoimmune disease. Immunol Rev 2008 223 : 143 155.
17. Anderson DE, et al. Paradoxical inhibition of T-cell function in response to CTLA-4 blockade; heterogeneity within the human T-cell population. Nat Med 2000 6 : 211 214.
18. Walunas TL, et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994 1 : 405 413.
19. Krummel MF, Allison JP. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med 1996 183 : 2533 2540.
20. Brunet JF, et al. A new member of the immunoglobulin superfamily - CTLA-4. Nature 1987 328 : 267 270.
21. Zhang Y, Allison JP. Interaction of CTLA-4 with AP50, a clathrin-coated pit adaptor protein. Proc Natl Acad Sci USA 1997 94 : 9273 9278.
22. Chuang E, Alegre ML, Duckett CS, Noel PJ, Vander Heiden MG, Thompson CB. Interaction of CTLA-4 with the clathrin-associated protein AP50 results in ligand-independent endocytosis that limits cell surface expression. J Immunol 1997 159 : 144 151.
23. Shiratori T, et al. Tyrosine phosphorylation controls internalization of CTLA-4 by regulating its interaction with clathrin-associated adaptor complex AP-2. Immunity 1997 6 : 583 589.
24. Chikuma S, Murakami M, Tanaka K, Uede T. Janus kinase 2 is associated with a box 1-like motif and phosphorylates a critical tyrosine residue in the cytoplasmic region of cytotoxic T lymphocyte associated molecule-4. J Cell Biochem 2000 78 : 241 250.
25. Miyatake S, Nakaseko C, Umemori H, Yamamoto T, Saito T. Src family tyrosine kinases associate with and phosphorylate CTLA-4 (CD152). Biochem Biophys Res Commun 1998 249 : 444 448.
26. Chuang E, et al. Regulation of cytotoxic T lymphocyte-associated molecule-4 by Src kinases. J Immunol 1999 162 : 1270 1277.
27. Wicker LS, et al. Fine mapping, gene content, comparative sequencing, and expression analyses support Ctla4 and Nramp1 as candidates for Idd5.1 and Idd5.2 in the nonobese diabetic mouse. J Immunol 2004 173 : 164 173.
28. Vijayakrishnan L, et al. An autoimmune disease-associated CTLA-4 splice variant lacking the B7 binding domain signals negatively in T cells. Immunity 2004 20 : 563 575.
29. Malquori L, Carsetti L, Ruberti G. The 3′ UTR of the human CTLA4 mRNA can regulate mRNA stability and translational efficiency. Biochim Biophys Acta 2008 1779 : 60 65.
30. Maier LM, Anderson DE, De Jager PL, Wicker LS, Hafler DA. Allelic variant in CTLA4 alters T cell phosphorylation patterns. Proc Natl Acad Sci U S A 2007 104 : 18607 18612.
31. Scholz C, Patton KT, Anderson DE, Freeman GJ, Hafler DA. Expansion of autoreactive T cells in multiple sclerosis is independent of exogenous B7 costimulation. J Immunol 1998 160 : 1532 1538.
32. Lovett-Racke AE, Trotter JL, Lauber J, Perrin PJ, June CH, Racke MK. Decreased dependence of myelin basic protein-reactive T cells on CD28-mediated costimulation in multiple sclerosis patients. A marker of activated/memory T cells. J Clin Invest 1998 101 : 725 730.
33. Viglietta V, Kent S, Orban T, Hafler D. GAD65-reactive T cells are activated in patients with autoimmune type 1a diabetes. J Clin Invest 2002 109 : 895 903.
34. Hunter K, Rainbow D, Plagnol V, Todd JA, Peterson LB, Wicker LS. Interactions between Idd5.1/Ctla4 and other type 1 diabetes genes. J Immunol 2007 179 : 8341 8349.
35. Hafler DA, et al. The International Multiple Sclerosis Genetics Consortium. Risk Alleles for Multiple Sclerosis Identified by a Genomewide Study. N Engl J Med 2007 357 : 851 862.
36. De Jager PL, et al. The role of the CD58 locus in multiple sclerosis. Proc Natl Acad Sci USA 2009 doi :.
37. Davis SJ, van der Merwe PA. CD2: an exception to the immunoglobulin superfamily concept? Science 1996 273 : 1241 1242.
38. Zheng Y, Josefowicz SZ, Kas A, Chu TT, Gavin MA, Rudensky AY. Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells. Nature 2007 445 : 936 940.
39. Baecher-Allan C, Wolf E, Hafler DA. MHC class II expression identifies functionally distinct human regulatory T cells. J Immunol 2006 176 : 4622 4631.
40. Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA. CD4+ CD25high regulatory cells in human peripheral blood. J Immunol 2001 167 : 1245 1253.
41. Baecher-Allan C, Viglietta V, Hafler DA. Human CD4+ CD25+ regulatory T cells. Semin Immunol 2004 16 : 89 98.
42. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+ CD25+ regulatory T cells. Nat Immunol 2003 4 : 330 336.
43. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003 299 : 1057 1061.
44. Khattri R, Cox T, Yasayko SA, Ramsdell F. An essential role for Scurfin in CD4+ CD25+ T regulatory cells. Nat Immunol 2003 4 : 337 342.
45. Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA. Loss of functional suppression by CD4+ CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med 2004 199 : 971 979.
46. Haas J, et al. Reduced suppressive effect of CD4+ CD25high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis. Eur J Immunol 2005 35 : 3343 3352.
47. Hong J, Li N, Zhang X, Zheng B, Zhang JZ. Induction of CD4+ CD25+ regulatory T cells by copolymer-I through activation of transcription factor Foxp3. Proc Natl Acad Sci USA 2005 102 : 6449 6454.
48. Huan J, et al. Decreased FOXP3 levels in multiple sclerosis patients. J Neurosci Res 2005 81 : 45 52.
49. Lindley S, Dayan CM, Bishop A, Roep BO, Peakman M, Tree TI. Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes. Diabetes 2005 54 : 92 99.
50. Brusko TM, Wasserfall CH, Clare-Salzler MJ, Schatz DA, Atkinson MA. Functional defects and the influence of age on the frequency of CD4+ CD25+ T-cells in type 1 diabetes. Diabetes 2005 54 : 1407 1414.
51. Putnam AL, Vendrame F, Dotta F, Gottlieb PA. CD4+ CD25high regulatory T cells in human autoimmune diabetes. J Autoimmun 2005 24 : 55 62.
52. Lebwohl M, Christophers E, Langley R, Ortonne JP, Roberts J, Griffiths CE. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 2003 139 : 719 727.
53. Larsen R, Ryder LP, Svejgaard A, Gniadecki R. Changes in circulating lymphocyte subpopulations following administration of the leucocyte function-associated antigen-3 (LFA-3)/IgG1 fusion protein alefacept. Clin Exp Immunol 2007 149 : 23 30.
54. Haider AS, et al. Novel insight into the agonistic mechanism of alefacept in vivo: differentially expressed genes may serve as biomarkers of response in psoriasis patients. J Immunol 2007 178 : 7442 7449.
55. Consortium WTCC. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007 447 : 661 678.
56. Plenge RM, et al. TRAF1-C5 as a risk locus for rheumatoid arthritis - a genomewide study. N Engl J Med 2007 357 : 1199 1209.
57. Kurylowicz A, et al. Association of CD40 gene polymorphism (C-1T) with susceptibility and phenotype of Graves' disease. Thyroid 2005 15 : 1119 1124.
58. Jacobson EM, et al. A CD40 Kozak sequence polymorphism and susceptibility to antibody-mediated autoimmune conditions: the role of CD40 tissue-specific expression. Genes Immun 2007 8 : 205 214.
59. Heward JM, Simmonds MJ, Carr-Smith J, Foxall H, Franklyn JA, Gough SC. A single nucleotide polymorphism in the CD40 gene on chromosome 20q (GD-2) provides no evidence for susceptibility to Graves' disease in UK Caucasians. Clin Endocrinol (Oxf) 2004 61 : 269 272.
60. Houston FA, et al. Role of the CD40 locus in Graves' disease. Thyroid 2004 14 : 506 509.
61. Jacobson EM, Concepcion E, Oashi T, Tomer Y. A Graves' disease-associated Kozak sequence single-nucleotide polymorphism enhances the efficiency of CD40 gene translation: a case for translational pathophysiology. Endocrinology 2005 146 : 2684 2691.
62. Graham DS, et al. Polymorphism at the TNF superfamily gene TNFSF4 confers susceptibility to systemic lupus erythematosus. Nat Genet 2008 40 : 83 89.
63. Delgado-Vega AM, et al. Replication of the TNFSF4 (OX40L) promoter region association with systemic lupus erythematosus. Genes Immun 2008 doi :.
64. Linton PJ, et al. Costimulation via OX40L expressed by B cells is sufficient to determine the extent of primary CD4 cell expansion and Th2 cytokine secretion in vivo. J Exp Med 2003 197 : 875 883.
65. Chen AI, et al. Ox40-ligand has a critical costimulatory role in dendritic cell:T cell interactions. Immunity 1999 11 : 689 698.
66. Kato H, et al. Essential role of OX40L on B cells in persistent alloantibody production following repeated alloimmunizations. J Clin Immunol 2004 24 : 237 248.
67. Wang HC, Klein JR. Multiple levels of activation of murine CD8(+) intraepithelial lymphocytes defined by OX40 (CD134) expression: effects on cell-mediated cytotoxicity, IFN-gamma, and IL-10 regulation. J Immunol 2001 167 : 6717 6723.
68. Song J, So T, Cheng M, Tang X, Croft M. Sustained survivin expression from OX40 costimulatory signals drives T cell clonal expansion. Immunity 2005 22 : 621 631.
69. So T, Song J, Sugie K, Altman A, Croft M. Signals from OX40 regulate nuclear factor of activated T cells c1 and T cell helper 2 lineage commitment. Proc Natl Acad Sci USA 2006 103 : 3740 3745.
70. Stuber E, Neurath M, Calderhead D, Fell HP, Strober W. Cross-linking of OX40 ligand, a member of the TNF/NGF cytokine family, induces proliferation and differentiation in murine splenic B cells. Immunity 1995 2 : 507 521.
71. Ikushima S, Inukai T, Inaba T, Nimer SD, Cleveland JL, Look AT. Pivotal role for the NFIL3/E4BP4 transcription factor in interleukin 3-mediated survival of pro-B lymphocytes. Proc Natl Acad Sci U S A 1997 94 : 2609 2614.
72. Manku H, Graham DS, Vyse TJ. Association of the co-stimulator OX40L with systemic lupus erythematosus. J Mol Med 2009 87 : 229 234.
73. Cornelis F, et al. New susceptibility locus for rheumatoid arthritis suggested by a genome-wide linkage study. Proc Natl Acad Sci USA 1998 95 : 10746 10750.
74. MacKay K, et al. Whole-genome linkage analysis of rheumatoid arthritis susceptibility loci in 252 affected sibling pairs in the United Kingdom. Arthritis Rheum 2002 46 : 632 639.
75. Jawaheer D, et al. A genomewide screen in multiplex rheumatoid arthritis families suggests genetic overlap with other autoimmune diseases. Am J Hum Genet 2001 68 : 927 936.
76. Scofield RH, et al. Thrombocytopenia identifies a severe familial phenotype of systemic lupus erythematosus and reveals genetic linkages at 1q22 and 11p13. Blood 2003 101 : 992 997.
77. Suzuki A, et al. Functional SNPs in CD244 increase the risk of rheumatoid arthritis in a Japanese population. Nat Genet 2008 40 : 1224 1229.
78. Schuhmachers G, Ariizumi K, Mathew PA, Bennett M, Kumar V, Takashima A. 2B4, a new member of the immunoglobulin gene superfamily, is expressed on murine dendritic epidermal T cells and plays a functional role in their killing of skin tumors. J Invest Dermatol 1995 105 : 592 596.
79. Mathew PA, et al. Cloning and characterization of the 2B4 gene encoding a molecule associated with non-MHC-restricted killing mediated by activated natural killer cells and T cells. J Immunol 1993 151 : 5328 5337.
80. Brown MH, Boles K, van der Merwe PA, Kumar V, Mathew PA, Barclay AN. 2B4, the natural killer and T cell immunoglobulin superfamily surface protein, is a ligand for CD48. J Exp Med 1998 188 : 2083 2090.
81. Chlewicki LK, Velikovsky CA, Balakrishnan V, Mariuzza RA, Kumar V. Molecular basis of the dual functions of 2B4 (CD244). J Immunol 2008 180 : 8159 8167.
82. Veillette A. NK cell regulation by SLAM family receptors and SAP-related adapters. Immunol Rev 2006 214 : 22 34.
83. Veillette A, Dong Z, Latour S. Consequence of the SLAM-SAP signaling pathway in innate-like and conventional lymphocytes. Immunity 2007 27 : 698 710.
84. Lanier LL. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol 2008 9 : 495 502.
85. Watzl C, Stebbins CC, Long EO. NK cell inhibitory receptors prevent tyrosine phosphorylation of the activation receptor 2B4 (CD244). J Immunol 2000 165 : 3545 3548.
86. Watzl C, Long EO. Natural killer cell inhibitory receptors block actin cytoskeleton-dependent recruitment of 2B4 (CD244) to lipid rafts. J Exp Med 2003 197 : 77 85.
87. Lee KM, et al. Cutting edge: the NK cell receptor 2B4 augments antigen-specific T cell cytotoxicity through CD48 ligation on neighboring T cells. J Immunol 2003 170 : 4881 4885.
88. Kambayashi T, Assarsson E, Chambers BJ, Ljunggren HG. Cutting edge: Regulation of CD8(+) T cell proliferation by 2B4/CD48 interactions. J Immunol 2001 167 : 6706 6710.
89. Hafler JP, et al. CD226 Gly307Ser association with multiple autoimmune diseases. Genes Immun 2009 10 : 5 10.
90. IMSGC T. Refining genetics associations in multiple sclerosis. Lancet Neurol 2008 7 : 567 569.
91. Shibuya K, et al. Physical and functional association of LFA-1 with DNAM-1 adhesion molecule. Immunity 1999 11 : 615 623.
92. Shirakawa J, Shibuya K, Shibuya A. Requirement of the serine at residue 329 for lipid raft recruitment of DNAM-1 (CD226). Int Immunol 2005 17 : 217 223.
93. Dardalhon V, et al. CD226 is specifically expressed on the surface of Th1 cells and regulates their expansion and effector functions. J Immunol 2005 175 : 1558 1565.
94. Gilfillan S, et al. DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors. J Exp Med 2008 205 : 2965 2973.
95. Tabata H, et al. Expression of TLiSA1 on T cells from patients with rheumatoid arthritis and systemic lupus erythematosus. Clin Immunol Immunopathol 1989 52 : 366 375.
96. Prokunina L, et al. A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat Genet 2002 32 : 666 669.
97. Velazquez-Cruz R, et al. Association of PDCD1 polymorphisms with childhood-onset systemic lupus erythematosus. Eur J Hum Genet 2007 15 : 336 341.
98. Thorburn CM, et al. Association of PDCD1 genetic variation with risk and clinical manifestations of systemic lupus erythematosus in a multiethnic cohort. Genes Immun 2007 8 : 279 287.
99. Sigurdsson S, et al. Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. Am J Hum Genet 2005 76 : 528 537.
100. Ferreiros-Vidal I, et al. Bias in association studies of systemic lupus erythematosus susceptibility due to geographical variation in the frequency of a programmed cell death 1 polymorphism across Europe. Genes Immun 2007 8 : 138 146.
101. Nielsen C, Laustrup H, Voss A, Junker P, Husby S, Lillevang ST. A putative regulatory polymorphism in PD-1 is associated with nephropathy in a population-based cohort of systemic lupus erythematosus patients. Lupus 2004 13 : 510 516.
102. Lee Y, Woo J, Choi S, Ji J, Song G. Association of programmed cell death 1 polymorphisms and systemic lupus erythematosus: a meta-analysis. Lupus 2009 18 : 9 15.
103. Suarez-Gestal M, Ferreiros-Vidal I, Ortiz JA, Gomez-Reino JJ, Gonzalez A. Analysis of the functional relevance of a putative regulatory SNP of PDCD1, PD1.3, associated with systemic lupus erythematosus. Genes Immun 2008 9 : 309 315.
104. Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999 11 : 141 151.
105. Okazaki T, Maeda A, Nishimura H, Kurosaki T, Honjo T. PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci USA 2001 98 : 13866 13871.
106. Yamazaki K, et al. Single nucleotide polymorphisms in TNFSF15 confer susceptibility to Crohn's disease. Hum Mol Genet 2005 14 : 3499 3506.
107. Tremelling M, et al. Contribution of TNFSF15 gene variants to Crohn's disease susceptibility confirmed in UK population. Inflamm Bowel Dis 2008 14 : 733 737.
108. Kakuta Y, Kinouchi Y, Negoro K, Takahashi S, Shimosegawa T. Association study of TNFSF15 polymorphisms in Japanese patients with inflammatory bowel disease. Gut 2006 55 : 1527 1528.
109. Migone TS, et al. TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity 2002 16 : 479 492.
110. Papadakis KA, et al. Dominant role for TL1A/DR3 pathway in IL-12 plus IL-18-induced IFN-gamma production by peripheral blood and mucosal CCR9+ T lymphocytes. J Immunol 2005 174 : 4985 4990.
111. Meylan F, et al. The TNF-family receptor DR3 is essential for diverse T cell-mediated inflammatory diseases. Immunity 2008 29 : 79 89.
112. Bamias G, et al. Expression, localization, and functional activity of TL1A, a novel Th1-polarizing cytokine in inflammatory bowel disease. J Immunol 2003 171 : 4868 4874.
113. Barrett JC, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet 2008 40 : 955 962.
114. Rioux JD, et al. Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nat Genet 2007 39 : 596 604.
115. Duerr RH, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006 314 : 1461 1463.
116. Aicher A, et al. Characterization of human inducible costimulator ligand expression and function. J Immunol 2000 164 : 4689 4696.
117. Yoshinaga SK, et al. Characterization of a new human B7-related protein: B7RP-1 is the ligand to the co-stimulatory protein ICOS. Int Immunol 2000 12 : 1439 1447.
118. Akbari O, et al. Antigen-specific regulatory T cells develop via the ICOS-ICOS-ligand pathway and inhibit allergen-induced airway hyperreactivity. Nat Med 2002 8 : 1024 1032.
119. Ito T, et al. Plasmacytoid dendritic cells prime IL-10-producing T regulatory cells by inducible costimulator ligand. J Exp Med 2007 204 : 105 115.
120. Yoshinaga SK, et al. T-cell co-stimulation through B7RP-1 and ICOS. Nature 1999 402 : 827 832.
121. Wang F, et al. The expression analysis of ICOS-L on activated T cells and immature dendritic cells as well as malignant B cells and Grave's-disease- derived thyroid tissues by two novel mAbs against human ICOS-L. Tissue Antigens 2007 69 : \62 72.
122. Marchini J, Howie B, Myers S, McVean G, Donnelly P. A new multipoint method for genome-wide association studies by imputation of genotypes. Nat Genet 2007 39 : 906 913.
123. Maier LM, et al. IL2RA genetic heterogeneity in multiple sclerosis and type 1 diabetes susceptibility and soluble interleukin-2 receptor production. PLoS Genet 2009 5 : e1000322.
124. Lowe CE, et al. Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes. Nat Genet 2007 39 : 1074 1082.
125. Maier LM, et al. Soluble IL-2RA levels in multiple sclerosis subjects and the effect of soluble IL-2RA on immune responses. J Immunol 2009 182 : 1541 1547.
126. Viglietta V, et al. CTLA4Ig treatment in patients with multiple sclerosis: an open-label, phase 1 clinical trial. Neurology 2008 71 : 917 924.
127. Genovese MC, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005 353 : 1114 1123.
128. Maier LM, Hafler DA. The developing mosaic of autoimmune disease risk. Nat Genet 2008 40 : 131 132.
129. Magistrelli G, et al. A soluble form of CTLA-4 generated by alternative splicing is expressed by nonstimulated human T cells. Eur J Immunol 1999 29 : 3596 3602.
130. Oaks MK, Hallett KM, Penwell RT, Stauber EC, Warren SJ, Tector AJ. A native soluble form of CTLA-4. Cell Immunol 2000 201 : 144 153.